Moderna cuts high end of 2025 revenue outlook on vaccine shipment delay in U.K.

Moderna reported a narrower-than-expected Q2 loss and beat revenue estimates, driven by a 27% reduction in operating expenses and broader cost-cutting initiatives, including a recent 10% workforce reduction. However, the company lowered the high end of its 2025 revenue outlook by $300 million to $2.2 billion due to a delay in UK vaccine shipments to Q1 2026, causing shares to fall over 5% in premarket trading. This mixed performance highlights Moderna's ongoing efforts to manage profitability through aggressive cost control amidst declining COVID-19 vaccine sales.

Analysis

Moderna presented a mixed operational and financial picture, beating second-quarter analyst expectations on profitability while simultaneously lowering its full-year 2025 revenue outlook. The company narrowed its projected 2025 revenue to a range of $1.5 billion to $2.2 billion, a $300 million reduction at the top end, citing a delay in U.K. vaccine shipments from late 2025 to Q1 2026. While management clarified this is a timing shift with no change to the contract's overall value, the revision prompted a greater than 5% decline in premarket shares. In contrast, Q2 results surpassed forecasts, with a loss per share of $2.13 against an expected $2.97 and revenue of $142 million beating the $113 million consensus. This outperformance was driven primarily by aggressive cost management, reflected in a 27% year-over-year decrease in operating expenses to $1.1 billion and a recently announced 10% workforce reduction. Despite the earnings beat, core business trends show strain; total Q2 revenue fell 41% from the prior year, and the company's new RSV vaccine posted "negligible" sales, missing a $5.9 million analyst estimate and signaling potential challenges in commercializing new products beyond its COVID-19 vaccine.

Key Decisions for Investors

• Investors should weigh the company's proven ability to manage its cost structure, which drove the Q2 earnings beat, against the significant top-line pressure from declining COVID-19 vaccine sales and a weak initial launch of its RSV vaccine.
• The lowered 2025 revenue guidance, despite being a timing issue, has clearly impacted near-term sentiment, and it is crucial to monitor for stabilization in the company's revenue outlook and execution on its product pipeline.
• Pay close attention to the sales trajectory of the new RSV vaccine in the upcoming quarters, as its commercial success is a critical test of Moderna's ability to diversify its revenue base and validate its post-pandemic growth strategy.